Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290877 | 1.00 | GRIK1 (0.43) | GRIK1ALOX5KMT2ACYP2D6CYP2C9 | |
| SCHEMBL7873373 | 0.96 | LTB4R (0.44) | ALOX5KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7876532 | 0.95 | LTB4R (0.46) | ALOX5LTB4R | |
| SCHEMBL7953565 | 0.92 | FDFT1 (0.43) | — | |
| SCHEMBL7876539 | 0.92 | SMN1; SMN2 (0.46) | KMT2ACYP2C9CYP2C19HPGDMEN1 | |
| SCHEMBL7946312 | 0.89 | DPP4 (0.38) | ALOX5KMT2ALMNA | |
| SCHEMBL7874835 | 0.89 | FFAR1 (0.44) | — | |
| SCHEMBL7431816 | 0.88 | PPARA (0.47) | KMT2ALMNAMEN1HTT | |
| SCHEMBL7879247 | 0.86 | GRIK1 (0.41) | GRIK1ALOX5KMT2ACYP2D6CYP2C9 | |
| SCHEMBL7879203 | 0.86 | LMNA (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |